Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)

Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)

Background: Real-world data (RWD) can contextualize clinical trial data. We present real-world evidence that supplemented the single-arm DESTINY-Breast01 trial, which assessed the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive...

Full description

Saved in:
Bibliographic Details
Main Authors: C. Courtinard, V. Barbet, R. Schiappa, F. Pilleul, S. Michiels, S. Dabakuyo, S. Gourgou, A. Jaffre, B. Asselain, L. Bosquet, K. Dunton, M. Rosenlund, Z. Liang, J. Cathcart, S. Delaloge
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
HER2+
metastatic breast cancer
real-world data
T-DXd
propensity score-matched
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820124000213
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2949820124000213

Similar Items